Patients with abnormal bleeding and endometrial proliferative and Hayprplastyk with irregular glands with and without atypia. Endometrial glandular hyperplasia
Conditions
Interventions
Intervention 1: In the first group, metformin 500 mg twice a day with megestrol 40 mg daily. Intervention 2: The second group of megestrol acetate 40 mg daily for 3 months will be prescribed.
Treatment - Drugs
In the first group, metformin 500 mg twice a day with megestrol 40 mg daily
The second group of megestrol acetate 40 mg daily for 3 months will be prescribed.
Sponsors
Vice chancellor for Research,Tabriz University Of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with abnormal uterine bleeding and havingdisordered proliferative or hyperplastic endometrium with or without atypia; Consent to participate. Exclusion criteria: Patients who have allergy to metformin; Patients with renal failure; nausea, vomiting, anorexia; anemia; cutaneous lesionsor not satisfied to participate in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endometrial pathology. Timepoint: Before surgery. Method of measurement: Pathological evaluation.;Histologic types of endometrial. Timepoint: Three months after the first dose. Method of measurement: Microscopic examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Manizhe Sayyah-Melli
Tabriz University Of Medical Sciences
Outcome results
None listed